Trial reportHaematologica2018
Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy.
Trial report in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Aspergillus fumigatus biology, immunopathogenicity and drug resistance.Nature reviews. Microbiology · 2025Review
- MiR-133 promotes the multidrug resistance of acute myeloid leukemia cells (HL-60/ADR) to daunorubicin.Cytotechnology · 2024Article
- Validating genetic variants in innate immunity linked to infectious events in acute myeloid leukemia post-induction chemotherapy.Genes and immunity · 2024Article
- An Update on Breakthrough Invasive Mold Infections.Mycopathologia · 2024Review
- Review
- Assessment of the Prevalence of Infections in Pediatric Patients With Acute Lymphoblastic Leukemia.Cureus · 2023Review
- Humoral Immunity Against Aspergillus fumigatus.Mycopathologia · 2023Review
- Article
- A Functional Polymorphism in IL-1B Is Associated With Immune Reconstitution Inflammatory Syndrome of Chronic Disseminated Candidiasis.Open forum infectious diseases · 2023Article
- Insights into the Relationship between Pentraxin-3 and Cancer.International journal of molecular sciences · 2022Review
- The EHA Research Roadmap: Infections in Hematology.HemaSphere · 2021Article
- Impact ofInternational journal of medical sciences · 2021Article
- Complementary Roles of Short and Long Pentraxins in the Complement-Mediated Immune Response toFrontiers in immunology · 2021Review
- Influenza-Associated Pulmonary Aspergillosis: A Local or Global Lethal Combination?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Chimeric Antigen Receptor T-cell Immunotherapy and Need for Prophylaxis for Invasive Mold Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Pentraxin-3 polymorphisms and pulmonary fungal disease in non-neutropenic patients.Annals of translational medicine · 2020Article
- Immune Parameters for Diagnosis and Treatment Monitoring in Invasive Mold Infection.Journal of fungi (Basel, Switzerland) · 2019Review
- IL-4 polymorphism influences susceptibility to Pneumocystis jirovecii pneumonia in HIV-positive patients.AIDS (London, England) · 2019Observational
- The Long Pentraxin PTX3 as a Humoral Innate Immunity Functional Player and Biomarker of Infections and Sepsis.Frontiers in immunology · 2019Review
- The Long Pentraxin PTX3 as a Link Between Innate Immunity, Tissue Remodeling, and Cancer.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.